List of Excipients in Branded Drug MEPHYTON

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	MEPHYTON	phytonadione	0187-1704	ACACIA
Bausch Health US LLC	MEPHYTON	phytonadione	0187-1704	CALCIUM PHOSPHATE
Bausch Health US LLC	MEPHYTON	phytonadione	0187-1704	LACTOSE
Bausch Health US LLC	MEPHYTON	phytonadione	0187-1704	MAGNESIUM STEARATE
Bausch Health US LLC	MEPHYTON	phytonadione	0187-1704	SILICON DIOXIDE
Bausch Health US LLC	MEPHYTON	phytonadione	0187-1704	STARCH, CORN

Mephyton Excipient Strategy and Commercial Opportunities for Phytonadione Tablets

Last updated: September 29, 2026

Mephyton is an oral phytonadione, or vitamin K1, tablet used to treat vitamin K deficiency-associated hypoprothrombinemia and selected anticoagulant-related coagulation disorders. Its commercial opportunity is driven less by patent exclusivity than by reliable low-dose manufacturing, stability control, hospital procurement, generic substitution, and differentiated packaging.

The principal excipient priorities are content uniformity, protection from light and oxidation, tablet disintegration, supply-chain reliability, and compatibility with patients who have lactose, gluten, or other excipient sensitivities. A competitively positioned generic or line extension would need to demonstrate pharmaceutical equivalence, bioequivalence where required, stability, and consistent supply rather than overcome a significant modern composition-of-matter patent estate.

What is Mephyton and how is phytonadione used?

Mephyton contains phytonadione, the synthetic form of vitamin K1. The product is marketed as an oral tablet, historically at a 5 mg strength. Phytonadione supports hepatic synthesis of vitamin K-dependent coagulation factors, including factors II, VII, IX, and X, and proteins C and S.

Product attribute	Mephyton
Active ingredient	Phytonadione, vitamin K1
Dosage form	Oral tablet
Common labeled strength	5 mg
Therapeutic area	Hematology, coagulation, anticoagulant reversal
FDA pathway	Approved prescription drug
Primary commercial alternatives	Generic phytonadione tablets, injectable phytonadione, other vitamin K products
Core formulation issue	Low-dose uniformity and stability of a light-sensitive lipophilic vitamin
Principal purchasing channels	Hospitals, pharmacies, anticoagulation clinics, long-term-care providers

The product label identifies oral phytonadione for hypoprothrombinemia caused by factors such as vitamin K deficiency, malabsorption, certain drug interactions, and coumarin-type anticoagulants, subject to the clinical limitations in the approved labeling.[1]

Oral Mephyton is not interchangeable with injectable phytonadione for every clinical situation. Route selection depends on the urgency of reversal, the patient’s ability to absorb oral medication, the cause of the coagulopathy, and the treating clinician’s assessment.

What excipients are used in Mephyton tablets?

Public labeling for Mephyton identifies conventional tablet excipients, including lactose, starch, magnesium stearate, and talc, although the precise formulation and supplier specifications should be verified against the current FDA label and the manufacturer’s regulatory filing.[1]

These excipients perform standard functions:

Excipient category	Typical function in a phytonadione tablet	Commercial relevance
Lactose	Diluent and tablet-bulk agent	Creates a potential lactose-sensitivity and labeling consideration
Starch	Binder, disintegrant, or filler	Supports compression and tablet breakup
Magnesium stearate	Lubricant	Controls ejection force and tooling performance
Talc	Glidant or anti-adherent	Improves powder flow and manufacturing robustness

The formulation challenge is not the total excipient load. It is the small active-ingredient quantity relative to the tablet mass and the chemical sensitivity of phytonadione. A manufacturer must distribute a low-dose, poorly water-soluble, lipophilic active uniformly through the blend while maintaining potency during storage.

Any proposed generic should treat the listed excipients as a starting point rather than a mandatory composition. FDA approval generally permits formulation differences if the product meets pharmaceutical equivalence, quality, labeling, and applicable bioequivalence requirements.

How should an excipient strategy address phytonadione stability?

The highest-value excipient strategy for Mephyton is a stability-led approach. Phytonadione is sensitive to light and can be vulnerable to oxidative degradation. The formulation and package should be developed together.

Protecting the active ingredient

A candidate formulation should evaluate:

• Light exposure during blending, compression, packaging, and dispensing.
• Oxygen exposure in headspace and through the package.
• Moisture uptake and its effect on tablet hardness, dissolution, and degradation.
• Excipient peroxides and other reactive impurities.
• Metal-ion contamination from raw materials or manufacturing equipment.
• Lubricant concentration and mixing time.
• Particle-size distribution and active-excipient segregation.

The most important development controls are likely to be blend uniformity, impurity profiling, photostability, accelerated stability, and packaging performance. The ICH Q1A and Q1B frameworks provide the relevant stability and photostability structure for pharmaceutical development.[2,3]

Selecting a protective package

A commercial product can obtain meaningful differentiation from packaging even where the tablet itself is conventional.

Packaging option	Potential advantage	Main trade-off
Aluminum-aluminum blister	Strong barrier to light, moisture, and oxygen	Higher unit cost and slower packaging throughput
PVC/PVdC blister	Lower cost and familiar pharmacy format	Lower barrier performance than high-protection structures
HDPE bottle with light protection	Efficient for larger counts and institutional supply	Repeated opening increases exposure risk
Unit-dose blister	Supports hospital administration and traceability	Higher packaging and labor cost
Desiccant bottle	Controls moisture in bottle presentations	Does not independently solve light exposure

For a low-volume prescription product, unit-dose blistering may be commercially attractive in hospitals and long-term-care settings. For retail pharmacy, a bottle may have lower packaging cost, but the manufacturer must establish in-use stability after repeated opening.

Managing excipient variability

Excipient suppliers can change particle size, moisture, peroxide level, bulk density, and lubrication behavior without changing the compendial name. A robust Mephyton generic should use tighter internal specifications for materials that affect degradation or blend uniformity.

The most commercially relevant controls include:

1. Peroxide limits for excipients capable of oxidative contribution.
2. Moisture limits for starches and lactose-containing blends.
3. Particle-size controls to reduce segregation.
4. Defined mixing order and validated blend time.
5. Supplier qualification for critical excipients.
6. Stability testing in the final commercial package.

What formulations are commercially attractive for Mephyton?

The main formulation opportunity is a reliable generic tablet rather than a complex novel dosage form.

Standard immediate-release tablet

A conventional immediate-release tablet is the lowest-risk route. It has a familiar manufacturing platform and a straightforward commercial message: equivalent phytonadione therapy at lower cost.

The main technical risks are:

• Low-dose content uniformity.
• Dissolution of a lipophilic active.
• Photodegradation.
• Variability in tablet hardness and disintegration.
• Excipient-driven impurity formation.

A formulation using lactose-free fillers, such as microcrystalline cellulose or selected dibasic calcium phosphate systems, could target institutions and patients with excipient restrictions. The substitution would require separate evaluation of compression, dissolution, stability, and bioequivalence.

Film-coated tablet

A film coat could improve light protection, swallowability, product identification, and handling. It can also add manufacturing complexity and may affect moisture transmission and disintegration.

A light-protective coating is most attractive when paired with protective primary packaging. Coating alone should not be treated as a replacement for package qualification.

Orally disintegrating or dispersible tablet

An orally disintegrating tablet could target patients who have difficulty swallowing or who need administration in long-term-care settings. Its commercial value is limited by the relatively established oral tablet market and the need to manage taste, mechanical strength, moisture sensitivity, and dose uniformity.

A dispersible presentation may also raise administration and dosing questions that are not present with the conventional 5 mg tablet. It would require a clear labeling and usability rationale.

Liquid or compounded oral formulations

A ready-to-use liquid could address pediatric, geriatric, or feeding-tube administration. The opportunity is technically more difficult because phytonadione is lipophilic and the formulation must control solubilization, emulsion stability, preservative performance, dose uniformity, and container compatibility.

A liquid product would be a line-extension strategy, not a simple generic substitution. It could command a higher price if it solves an identifiable administration problem, but it would carry greater formulation and regulatory risk.

When does Mephyton lose exclusivity?

Mephyton is an older small-molecule product. Its commercial position is not based on a current patent-protected active ingredient. The relevant competitive barriers are product approval, manufacturing quality, supply reliability, brand recognition, and pharmacy purchasing behavior.

Patent and regulatory position

Protection category	Assessment
Active ingredient patent	No practical modern composition-of-matter barrier for phytonadione
Core tablet formulation patent	No widely recognized current barrier comparable to newer specialty drugs
Method-of-use patents	Limited commercial relevance for the established vitamin K1 indications
FDA exclusivity	Historic exclusivity periods, if any, would not protect the current market from ordinary generic competition
Orange Book relevance	Relevant for confirming current listed patents and exclusivity; not expected to show a strong contemporary patent wall
Generic pathway	Abbreviated New Drug Application, subject to FDA requirements
Biosimilar risk	Not applicable; phytonadione is a chemically synthesized small molecule

The Orange Book remains the controlling public source for FDA-listed patents and exclusivity associated with approved products.[4] For an old phytonadione tablet, the principal question is whether any current listing creates a meaningful delay or litigation risk for an ANDA applicant. A generic developer should not assume that historical brand protection remains active.

Are Paragraph IV challenges likely for Mephyton?

Paragraph IV risk is likely to be limited because Mephyton is an old small-molecule product with no apparent high-value patent estate comparable to recently approved specialty medicines.

A Paragraph IV certification would matter only if a current Orange Book-listed patent covered the reference product and had sufficient remaining term to affect launch timing. In the absence of such a patent, an applicant may rely on the applicable ANDA certification pathway without needing to litigate a significant formulation or method-of-use patent.

The practical competitive risks are more likely to involve:

• FDA review of pharmaceutical equivalence.
• Demonstration of adequate stability.
• Manufacturing-site inspection findings.
• Drug-shortage exposure.
• Raw-material qualification.
• Commercial access to hospital group purchasing organizations.
• Brand or distributor contracting.

What FDA regulatory issues affect a Mephyton generic?

A generic phytonadione tablet would generally need to satisfy FDA requirements for:

• Same active ingredient, dosage form, strength, route, and conditions of use.
• Pharmaceutical equivalence.
• Bioequivalence where applicable.
• Identity, strength, quality, purity, and potency.
• Appropriate inactive-ingredient justification.
• Stability through the proposed shelf life.
• Container-closure performance.
• Dissolution and dosage-unit uniformity.
• Current good manufacturing practice compliance.

The inactive-ingredient strategy should be conservative for the initial ANDA. Major changes to excipients can increase development time, raise bioequivalence questions, and create stability risks. A manufacturer seeking differentiation should first establish a conventional product, then evaluate lactose-free, film-coated, unit-dose, or liquid extensions.

How strong is the Mephyton patent estate?

The Mephyton patent estate appears commercially weak compared with branded drugs launched within the past 15 years. Phytonadione has been used clinically for decades, and the active ingredient is not protected by a contemporary composition patent.

Patent strength should be separated into four categories:

Category	Relative strength	Commercial implication
Active ingredient	Low	Generic entry is technically feasible
Conventional tablet	Low	Standard formulation replication is possible
Novel delivery system	Potentially moderate	Could support a line extension if claims are technically narrow and enforceable
Manufacturing process	Variable	May protect a specific process but rarely prevents all tablet competition

A new patent could arise from a genuinely differentiated formulation, such as a stable dispersible system, novel solid dispersion, specialized coating, or manufacturing process. Such a patent would protect the new formulation only to the extent its claims cover competitor products or processes. It would not restore broad exclusivity to conventional phytonadione tablets.

What commercial opportunities exist for Mephyton excipients and formulations?

The strongest opportunities are incremental and operational.

1. Lactose-free generic product

A lactose-free product could address institutional formulary preferences and patients who avoid lactose. The opportunity is most credible if the product maintains the same tablet size, dissolution profile, stability, and packaging efficiency as the reference product.

2. Light-protective packaging

A high-barrier blister or unit-dose presentation could create a quality and handling advantage. This is particularly relevant for hospital inventories, automated dispensing cabinets, and long-term-care medication carts.

3. Stable dispersible or liquid formulation

A patient-friendly formulation could expand use among patients with swallowing limitations or enteral feeding requirements. It would require more development work but could reduce dependence on tablet swallowing.

4. Institutional supply contracts

A generic manufacturer could compete through:

• Reliable backorders and safety stock.
• Unit-dose packaging.
• Barcode and serialization compliance.
• Simplified case configuration.
• Consistent tablet appearance.
• Contract pricing for hospitals and distributors.

5. Combination portfolio strategy

A supplier with injectable phytonadione, oral phytonadione, and other coagulation-support products could offer a broader hospital portfolio. The commercial benefit would come from contracting and procurement efficiency rather than patent leverage.

How does Mephyton compare with competing vitamin K products?

Product type	Main advantage	Main limitation	Commercial position
Oral phytonadione tablet	Simple administration and low manufacturing complexity	Absorption depends on gastrointestinal function	Generic and retail opportunity
Injectable phytonadione	Useful when oral administration is unsuitable	Injection-related risks and higher handling requirements	Hospital-centered market
Vitamin K-containing supplements	Consumer access and broader retail distribution	Not equivalent to prescription treatment for coagulopathy	Consumer-health channel
Novel oral liquid or dispersible formulation	Administration flexibility	Higher formulation and packaging complexity	Niche line-extension opportunity

Mephyton competes primarily on availability, price, and prescriber familiarity. It does not compete through a protected biologic mechanism or a technically complex delivery system.

What generic launch scenarios exist for Mephyton?

Base case: standard generic tablet

The most likely launch path is an immediate-release generic tablet using conventional excipients and protective packaging. Price competition would be significant, and supply reliability would be the principal differentiator.

Premium generic: lactose-free or unit-dose product

A lactose-free or hospital-oriented unit-dose product could support improved contracting economics. The premium would depend on whether purchasers value the operational benefit enough to offset higher packaging costs.

Specialty line extension

A dispersible or liquid formulation could support a differentiated commercial position. The addressable market would be smaller, but the product could face less direct competition if it solves administration problems not addressed by standard tablets.

Supply-constrained market

If manufacturers exit because of low margins, a reliable supplier could gain share without owning meaningful patent rights. This strategy depends on manufacturing efficiency, API access, inventory planning, and FDA-compliant quality systems.

What revenue exposure and market risks apply?

Mephyton-specific revenue is not generally disclosed in public company filings as a standalone product metric. The revenue opportunity should therefore be modeled from prescription volume, institutional demand, generic price erosion, channel mix, and supply availability rather than historical brand sales.

Key risks include:

• Rapid price erosion after multiple generic entrants.
• Low absolute tablet pricing.
• API and excipient supply interruptions.
• Product recalls caused by stability or content-uniformity failures.
• Hospital preference for injectable vitamin K in urgent settings.
• Limited clinical differentiation among conventional tablets.
• Reimbursement pressure in retail pharmacy.
• Low return on specialized formulation development.

The most defensible commercial strategy is a low-cost, high-reliability tablet supported by light-protective packaging and a second product designed for patients who cannot swallow conventional tablets.

Key Takeaways

• Mephyton is an oral phytonadione, or vitamin K1, tablet product.
• Its main formulation challenges are low-dose content uniformity, light sensitivity, oxidation control, and dissolution.
• Public labeling identifies conventional excipients such as lactose, starch, magnesium stearate, and talc.[1]
• A modern, high-value patent barrier is not apparent for conventional phytonadione tablets.
• Biosimilar risk does not apply because phytonadione is a chemically synthesized small molecule.
• The strongest generic opportunities are lactose-free formulations, unit-dose blister packaging, and reliable hospital supply.
• Orally disintegrating, dispersible, or liquid products could support higher-value niche positioning but require greater development investment.
• Commercial success will depend more on manufacturing quality, FDA compliance, supply reliability, and contracting than on patent exclusivity.

FAQs

Can a lactose-free Mephyton generic be developed?

Yes. A generic manufacturer can replace lactose with another suitable diluent or filler, provided the product meets FDA requirements for quality, stability, dissolution, pharmaceutical equivalence, and bioequivalence where applicable.

Is phytonadione the same as vitamin K2?

No. Phytonadione is vitamin K1. Vitamin K2 compounds, including menaquinones, are chemically different and are not interchangeable with prescription phytonadione products.

Does Mephyton require light-protective packaging?

A protective package is commercially and technically prudent because phytonadione is light-sensitive. The selected container-closure system should be qualified through photostability and stability testing.

Could a new formulation of phytonadione receive patent protection?

Yes. A novel, non-obvious formulation, delivery system, or manufacturing process could be patentable. Protection would generally be narrower than a composition-of-matter patent and would cover only the claimed technology.

Is an oral phytonadione tablet a substitute for injectable vitamin K?

Not in every clinical setting. Route selection depends on urgency, absorption, indication, and patient condition. The approved labeling and clinical judgment control product selection.[1]

References

1. U.S. Food and Drug Administration. (n.d.). Mephyton (phytonadione) tablets prescribing information. DailyMed.
2. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products.
3. International Council for Harmonisation. (1996). Q1B: Photostability testing of new drug substances and medicinal products.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.